Abstract:A subset of cardiomyocytes acquires a senescence‐associated secretory phenotype (SASP) when subjected to doxorubicin (Dox). SASP cardiomyocytes affect healthy non‐senescent cardiomyocytes, rendering them senescent through delivery of exosomes. Clearance of senescent cardiomyocytes using the Bcl‐2 inhibitor ABT‐199 alleviates senescence of cardiomyocytes and prevents chemotherapy‐related cardiotoxicity. Our findings suggest that SASP senescent cardiomyocytes are a significant component of the pathogenesis of Dox‐related cardiotoxicity and could be a new therapeutic target for Dox‐induced cardiac injury. Doxorubicin (Dox), an anthracycline antibiotic, is widely used in cancer treatment. Although its antitumor efficacy appears significant, its clinical use is greatly restricted by its induction of cardiotoxicity. Cardiac senescence drives the Dox‐induced cardiotoxicity, but whether diminishing these senescent cardiomyocytes could alleviate the cardiotoxicity remains unclear. Here, we assessed whether senescent cardiomyocytes have a senescence‐associated secretory phenotype (SASP) that affects healthy non‐senescent cardiomyocytes, rendering them senescent via the delivery of exosomes. Additionally, we explored whether targeting SASP senescent cardiomyocytes using a Bcl‐2 inhibitor could alleviate cardiotoxicity. Cardiac damage was induced in a mouse model of continuous Dox treatment in vivo, and cardiomyocytes in vitro. Immunofluorescence of the senescence markers of Cdkn2a, Cdkn1a and γ‐H2A.X was used to assess the SASP in the Dox‐treated heart. To explore the molecular mechanisms involved, the Bcl‐2 inhibitor ABT‐199 was employed to eliminate SASP senescent cardiomyocytes. We show that the cardiomyocytes acquire a SASP during Dox treatment. The senescent cardiomyocytes upregulated Bcl‐2, although treatment of mice with ABT‐199 selectively eliminated SASP senescent cardiomyocytes involved in Dox‐induced cardiotoxicity, thus leading to partial alleviation of Dox‐induced cardiotoxicity. Moreover, we concluded that SASP factors secreted by senescent cardiomyocytes induced by Dox renders otherwise healthy cardiomyocytes senescent through exosome delivery. Our findings suggest that SASP senescent cardiomyocytes are a significant component of the pathogenesis of Dox‐dependent cardiotoxicity and indicate that targeting the clearance of SASP senescent cardiomyocytes could be a new therapeutic approach for Dox‐induced cardiac injury.

Protective effect of secretory APE1/Ref‐1 on doxorubicin‐induced cardiotoxicity via suppression of ROS and p53 pathway

Adiponectin agonist ADP355 ameliorates doxorubicin-induced cardiotoxicity by decreasing cardiomyocyte apoptosis and oxidative stress

Small-molecule mediated MuRF1 inhibition protects from doxorubicin-induced cardiac atrophy and contractile dysfunction

The apelin-13 peptide protects the heart against apoptosis through the ERK/MAPK and PI3K/AKT signaling pathways.

Cardioprotective Effect of Paeonol on Chronic Heart Failure Induced by Doxorubicin via Regulating the miR-21-5p/S-Phase Kinase-Associated Protein 2 Axis

Peptidomics Analysis Reveals Peptide PDCryab1 Inhibits Doxorubicin-Induced Cardiotoxicity

Neuraminidase1 Inhibitor Protects Against Doxorubicin-Induced Cardiotoxicity via Suppressing Drp1-Dependent Mitophagy

Paeonol protects against doxorubicin-induced cardiotoxicity by promoting Mfn2-mediated mitochondrial fusion through activating the PKCε-Stat3 pathway

The Cardioprotective Mechanism of Phenylaminoethyl Selenides (PAESe) Against Doxorubicin-Induced Cardiotoxicity Involves Frataxin

Apigenin alleviates doxorubicin‐induced myocardial pyroptosis by inhibiting glycogen synthase kinase‐3β in vitro and in vivo

Alginate Oligosaccharide Prevents Acute Doxorubicin Cardiotoxicity by Suppressing Oxidative Stress and Endoplasmic Reticulum-Mediated Apoptosis

Dapagliflozin Mitigates Doxorubicin-Caused Myocardium Damage by Regulating AKT-Mediated Oxidative Stress, Cardiac Remodeling, and Inflammation

The impact of PPAR-γ/Nrf-2/HO-1, NF-κB/IL-6/ Keap-1, and Bcl-2/caspase-3/ATG-5 pathways in mitigation of DOX-induced cardiotoxicity in an animal model: The potential cardioprotective role of oxyresveratrol and/or dapagliflozin

Peficitinib ameliorates doxorubicin-induced cardiotoxicity by suppressing cellular senescence and enhances its antitumor activity

The Abl1 tyrosine kinase is a key player in doxorubicin-induced cardiomyopathy and its p53/p73 cell death mediated signaling differs in atrial and ventricular cardiomyocytes

Saikosaponin D Alleviates DOX-induced Cardiac Injury In Vivo and In Vitro

AP39, a novel mitochondria-targeted hydrogen sulfide donor ameliorates doxorubicin-induced cardiotoxicity by regulating the AMPK/UCP2 pathway

Depletion of SASP senescent cardiomyocytes with senolytic drugs confers therapeutic effects in doxorubicin‐related cardiotoxicity

Dexrazoxane Protects Cardiomyocyte from Doxorubicin-Induced Apoptosis by Modulating Mir-17-5p

Procyanidins produce significant attenuation of doxorubicin-induced cardiotoxicity via suppression of oxidative stress

SIRT1 Suppresses Doxorubicin-Induced Cardiotoxicity by Regulating the Oxidative Stress and P38mapk Pathways